HR Execs on the Move

Guardian Pharmacy

www.guardianpharmacy.net

 
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Jaleynne Raymond
Director of Total Rewards Human Resources Information System Profile

Similar Companies

Extreme Performance Inc

Extreme Performance Inc is a Littleton, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Triax Pharmaceuticals

Triax Pharmaceuticals is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abacus Medicine A/S

The Abacus Medicine Group creates better access to medicine. We help life-critical medicines become more widely available.

Sunrise Pharmaceutical Inc

Sunrise Pharmaceutical Inc is a Rahway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.